Reversibility of neuropathology in Tay-Sachs-related diseases.
The GM2 gangliosidoses are progressive neurodegenerative disorders due to defects in the lysosomal β-N-acetylhexosaminidase system. Accumulation of β-hexosaminidases A and B substrates is presumed to cause this fatal condition. An authentic mouse model of Sandhoff disease (SD) with pathological characteristics resembling those noted in infantile GM2 gangliosidosis has been described. We have shown that expression of β-hexosaminidase by intracranial delivery of recombinant adeno-associated viral vectors to young adult SD mice can prevent many features of the disease and extends lifespan. To investigate the nature of the neurological injury in GM2 gangliosidosis and the extent of its reversibility, we have examined the evolution of disease in the SD mouse; we have moreover explored the effects of gene transfer delivered at key times during the course of the illness. Here we report greatly increased survival only when the therapeutic genes are expressed either before the disease is apparent or during its early manifestations. However, irrespective of when treatment was administered, widespread and abundant expression of β-hexosaminidase with consequent clearance of glycoconjugates, α-synuclein and ubiquitinated proteins, and abrogation of inflammatory responses and neuronal loss was observed. We also show that defects in myelination occur in early life and cannot be easily resolved when treatment is given to the adult brain. These results indicate that there is a limited temporal opportunity in which function and survival can be improved-but regardless of resolution of the cardinal pathological features of GM2 gangliosidosis, a point is reached when functional deterioration and death cannot be prevented.
Department of Medicine, University of Cambridge, Cambridge, UK and.
María-Begoña
MB
Cachón-González
Susan Z
SZ
Wang
Robin
R
Ziegler
Seng H
SH
Cheng
Timothy M
TM
Cox
D000818:Animals; D001921:Brain / Q000187:drug effects / Q000201:enzymology*; D000229:Dependovirus / Q000235:genetics; D004195:Disease Models, Animal; D005678:G(M2) Ganglioside / Q000235:genetics / Q000378:metabolism; D015316:Genetic Therapy / Q000379:methods; D005822:Genetic Vectors / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D015552:Injections, Intralesional; D051379:Mice; D018345:Mice, Knockout; D008822:Mice, Transgenic; D012497:Sandhoff Disease / Q000235:genetics* / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D013661:Tay-Sachs Disease / Q000473:pathology*; D025801:Ubiquitin / Q000378:metabolism; D051844:alpha-Synuclein / Q000378:metabolism; D001619:beta-N-Acetylhexosaminidases / Q000235:genetics* / Q000378:metabolism
D025801:Ubiquitin; D051844:alpha-Synuclein; D005678:G(M2) Ganglioside; D001619:beta-N-Acetylhexosaminidases